

# Emilio Bria

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3512721/emilio-bria-publications-by-year.pdf>

**Version:** 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

298 papers	6,424 citations	40 h-index	68 g-index
319 ext. papers	7,821 ext. citations	5.2 avg, IF	5.45 L-index

#	Paper	IF	Citations
298	A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERA-VOLT registry.. <i>Journal of Thoracic Oncology</i> , <b>2022</b> ,	8.9	1
297	Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.. <i>Human Vaccines and Immunotherapeutics</i> , <b>2022</b> , 1-10	4.4	1
296	Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches.. <i>Nutrients</i> , <b>2022</b> , 14,	6.7	1
295	New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis.. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 106, 102377	14.4	2
294	Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2200338	2.2	7
293	The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 792385	5.3	0
292	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211059873	5.4	1
291	Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 1341-1356	3.7	3
290	Nutritional Support in Lung Cancer Patients: The State of the Art. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, e584-e594	5.4	8
289	Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	3
288	Survival Analysis in Single N2 Station Lung Adenocarcinoma: The Prognostic Role of Involved Lymph Nodes and Adjuvant Therapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
287	Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study). <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
286	Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 650293	5.3	4
285	Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Radiologia Medica</i> , <b>2021</b> , 126, 1117-1128	6.5	6
284	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4311-4324	12.9	5
283	Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	5
282	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , <b>2021</b> , 150, 224-231	7.5	8

281	Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. <i>Oncologist</i> , <b>2021</b> , 26, e1854-e1861	5.7	1
280	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 97, 102202	14.4	4
279	Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Molecular Pathology</i> , <b>2021</b> , 2, 207-222	0.4	
278	A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 3369-3384	4.4	2
277	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. <i>Scientific Reports</i> , <b>2021</b> , 11, 13770	4.9	0
276	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 1583-1592	7.4	4
275	Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211006947	5.4	1
274	PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 351-360	4.9	2
273	Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC. <i>Current Problems in Cancer</i> , <b>2021</b> , 46, 100787	2.3	2
272	Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus -paclitaxel for Advanced Pancreatic Adenocarcinoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 688889	5.3	2
271	Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma. <i>World Journal of Gastrointestinal Surgery</i> , <b>2021</b> , 13, 885-903	2.4	2
270	Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study. <i>Breast</i> , <b>2021</b> , 60, 6-14	3.6	1
269	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2020</b> , 39, 279	12.8	12
268	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , <b>2020</b> , 12,	6.6	27
267	Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 531-542	3.5	2
266	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 498-508.e2	4.9	27
265	Mediastinal Up-Staging During Surgery in Non-Small-Cell Lung Cancer: Which Mediastinal Lymph Node Metastasis Patterns Better Predict The Outcome? A Multicenter Analysis. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 464-471.e1	4.9	3
264	c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. <i>Cancers</i> , <b>2020</b> , 12,	6.6	21

263	Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren Classification in Pan-Cancer Analysis Era?. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
262	Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 687-699	4	21
261	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , <b>2020</b> , 50, 56-63	3.6	3
260	Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 77, 121-122	3.9	16
259	Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome. <i>ESMO Open</i> , <b>2020</b> , 5, e000689	6	4
258	Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis. <i>Clinical Nutrition</i> , <b>2020</b> , 39, 2045-2054	5.9	36
257	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 69-76.e4	3.3	6
256	Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more?. <i>Breast Journal</i> , <b>2020</b> , 26, 1458-1460	1.2	2
255	Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	6
254	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$ : a multicenter study with external validation <b>2020</b> , 8,		29
253	Effects of nutritional interventions on nutritional status in patients with gastric cancer: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Nutrition ESPEN</i> , <b>2020</b> , 38, 28-42	1.3	20
252	Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages. <i>Cancer Discovery</i> , <b>2020</b> , 10, 1758-1773	24.4	17
251	AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	6
250	The Facts about Food after Cancer Diagnosis: A Systematic Review of Prospective Cohort Studies. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	6
249	External validation of the N descriptor in the proposed tumour-node-metastasis subclassification for lung cancer: the crucial role of histological type, number of resected nodes and adjuvant therapy. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2020</b> , 58, 1236-1244	3	3
248	Prognostic score for survival with pulmonary carcinoids: the importance of associating clinical with pathological characteristics. <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2020</b> , 31, 315-323	1.8	4
247	Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , <b>2020</b> , 136, 195-203	7.5	24
246	Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series. <i>Journal of Personalized Medicine</i> , <b>2020</b> , 10,	3.6	2

245	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 1917-1929	7.5	3
244	Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. <i>Cancers</i> , <b>2019</b> , 11,	6.6	18
243	Crizotinib in -Deregulated or -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 7312-7319	12.9	80
242	Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. <i>Seminars in Oncology</i> , <b>2019</b> , 46, 65-72	5.5	10
241	Muscle derangement and alteration of the nutritional machinery in NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 141, 43-53	7	10
240	Pembrolizumab as first-line treatment for metastatic uveal melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 1179-1185	7.4	32
239	Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, e514-e516	4.9	6
238	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1651-1661	8.9	44
237	Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 139, 83-86	7	5
236	Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 232	5.3	16
235	Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?". <i>Current Treatment Options in Oncology</i> , <b>2019</b> , 20, 23	5.4	3
234	PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. <i>Cancers</i> , <b>2019</b> , 11,	6.6	47
233	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. <i>Lung Cancer</i> , <b>2019</b> , 134, 121-126	5.9	1
232	Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?. <i>Cancers</i> , <b>2019</b> , 11,	6.6	23
231	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. <i>Lung Cancer</i> , <b>2019</b> , 134, 210-217	5.9	8
230	Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	15
229	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. <i>PLoS ONE</i> , <b>2019</b> , 14, e0224027	3.7	4
228	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 7652014	4.3	21

227	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , <b>2019</b> , 11, 921-930	3.8	5
226	PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. <i>Journal of Immunotherapy</i> , <b>2019</b> , 42, 269-273	5	10
225	Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. <i>Oncologist</i> , <b>2019</b> , 24, 1424-1431	5.7	11
224	Lymph-node ratio predicts survival among the different stages of non-small-cell lung cancer: a multicentre analysis <i>European Journal of Cardio-thoracic Surgery</i> , <b>2019</b> , 55, 405-412	3	22
223	A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. <i>Cancer Biology and Therapy</i> , <b>2019</b> , 20, 192-200	4.6	17
222	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach <b>2019</b> , 14, e0224027		
221	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach <b>2019</b> , 14, e0224027		
220	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach <b>2019</b> , 14, e0224027		
219	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach <b>2019</b> , 14, e0224027		
218	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach <b>2019</b> , 14, e0224027		
217	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach <b>2019</b> , 14, e0224027		
216	The obesity paradox in cancer: clinical insights and perspectives. <i>Eating and Weight Disorders</i> , <b>2018</b> , 23, 185-193	3.6	28
215	Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2018</b> , 472, 567-577	5.1	41
214	Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 124, 21-28	7	11
213	Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey. <i>Supportive Care in Cancer</i> , <b>2018</b> , 26, 1841-1849	3.9	5
212	The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e645-e653	3.3	68
211	Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 568-575	8.9	9
210	The development of PARP as a successful target for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 161-175	3.5	12



209	Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy. <i>European Journal of Clinical Nutrition</i> , <b>2018</b> , 72, 772-779	5.2	18
208	Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease. <i>Clinical Respiratory Journal</i> , <b>2018</b> , 12, 1150-1159	1.7	2
207	Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 93-104	4.9	31
206	Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2018</b> , 26, 383-387	1.9	28
205	Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 191-198	4.9	1
204	Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. <i>Carcinogenesis</i> , <b>2018</b> , 39, 971-980	4.6	32
203	Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 129, 54-66	7	19
202	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 937-945	5.4	10
201	mTOR Cross-Talk in Cancer and Potential for Combination Therapy. <i>Cancers</i> , <b>2018</b> , 10,	6.6	78
200	Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. <i>Scientific Reports</i> , <b>2018</b> , 8, 7119	4.9	25
199	Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 70, 112-117	14.4	11
198	Role of mTOR Signaling in Tumor Microenvironment: An Overview. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	74
197	Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 542-542	2.2	1
196	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , <b>2018</b> , 10, S1564-S1580	2.6	35
195	Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?. <i>Seminars in Oncology</i> , <b>2018</b> , 45, 176-180	5.5	3
194	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1543-1552	13.4	380
193	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1692-1704	8.9	49
192	Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. <i>Targeted Oncology</i> , <b>2018</b> , 13, 649-655	5	13

191	Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2017</b> , 25, 39-43	1.9	7
190	Patients' perception of chemotherapy side effects: Expectations, doctor-patient communication and impact on quality of life - An Italian survey. <i>European Journal of Cancer Care</i> , <b>2017</b> , 26, e12618	2.4	58
189	Clinical results of randomized trials and real-world data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 497-506	5.4	4
188	Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 55, 83-95	14.4	48
187	Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis. <i>Experimental and Molecular Pathology</i> , <b>2017</b> , 102, 276-279	4.4	11
186	Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors. <i>Cancer Genetics</i> , <b>2017</b> , 210, 28-33	2.3	2
185	Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. <i>Lung Cancer</i> , <b>2017</b> , 111, 30-37	5.9	20
184	Prognostic impact of proliferation for resected early stage pure invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. <i>Breast</i> , <b>2017</b> , 35, 21-26	3.6	12
183	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. <i>Immunotherapy</i> , <b>2017</b> , 9, 579-587	3.8	10
182	OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC). <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S266-S267	8.9	4
181	ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes. <i>Cancer Biomarkers</i> , <b>2017</b> , 18, 215-220	3.8	3
180	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. <i>Expert Review of Molecular Diagnostics</i> , <b>2017</b> , 17, 1055-1069	3.8	19
179	Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 60, 1-11	14.4	17
178	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. <i>Journal of Pathology</i> , <b>2017</b> , 241, 488-500	9.4	122
177	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5030-5030	2.2	3
176	MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. <i>Annals of Translational Medicine</i> , <b>2017</b> , 5, 2	3.2	32
175	Patients with metastatic castration-resistant prostate cancer (mCRPC) are primary resistant (PR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e585-e585	2.2	
174	Patients with metastatic castration-resistant prostate cancer (mCRPC) who are long-term responders (LTR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 254-254	2.2	



173	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)- based third-line treatment: Final results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 230-230	2.2	
172	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)- based third line treatment: Final results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e16521-e16521	2.2	
171	Co-existence of KRAS and LKB1 mutation as predictor of resistance to Erlotinib: Customized next-generation sequencing (NGS) of TAILOR trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e20631-e20631	2.2	1
170	A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 539-539	2.2	
169	Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis. <i>Scientific Reports</i> , <b>2016</b> , 6, 22982	4.9	13
168	Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment. <i>Breast</i> , <b>2016</b> , 30, 151-155	3.6	23
167	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. <i>Oncologist</i> , <b>2016</b> , 21, 283-91	5.7	35
166	Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. <i>Future Oncology</i> , <b>2016</b> , 12, 333-42	3.6	22
165	Tubulin inhibitors in non-small cell lung cancer: looking back and forward. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 1113-29	4	18
164	BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. <i>Lung Cancer</i> , <b>2016</b> , 95, 73-81	5.9	14
163	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 98, 254-63	7	1
162	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 30-6	8.7	39
161	Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS9104-TPS9104	2.2	4
160	Cellular and molecular biology of small cell lung cancer: an overview. <i>Translational Lung Cancer Research</i> , <b>2016</b> , 5, 2-15	4.4	38
159	Propensity score analysis investigating the role of hormonal maintenance (HM) for advanced breast carcinoma with luminal subtype (ABC-Lum): Implication for prognostic modeling, post-progression and conditional survival (PPS/CS).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 545-545	2.2	
158	Cut-off analysis and prognostic relevance of Ki67 for resected early stage pure invasive lobular breast carcinoma (ILC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 544-544	2.2	
157	Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. <i>Translational Lung Cancer Research</i> , <b>2016</b> , 5, 301-21	4.4	33
156	ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. <i>Respiratory Research</i> , <b>2016</b> , 17, 105	7.3	9

155	Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival. <i>Breast</i> , <b>2016</b> , 29, 24-30	3.6	8
154	International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1153-69	8.9	5
153	Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 919-25	3.6	66
152	Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage pure and mixed lobular breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2016</b> , 35, 50	12.8	4
151	Interfering with CCL5/CCR5 at the Tumor-Stroma Interface. <i>Cancer Cell</i> , <b>2016</b> , 29, 437-439	24.3	14
150	Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over?. <i>Expert Opinion on Investigational Drugs</i> , <b>2016</b> , 25, 635-8	5.9	
149	PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1519-25	10.3	109
148	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 2253-2266	4	22
147	The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. <i>Expert Opinion on Biological Therapy</i> , <b>2015</b> , 15, 1359-70	5.4	11
146	Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , <b>2015</b> , 88, 319-24	5.9	4
145	Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, 399-405	4.9	17
144	Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?. <i>Future Oncology</i> , <b>2015</b> , 11, 107-19	3.6	11
143	An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 1143-61	5.9	5
142	Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 96, 498-506	7	40
141	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 93, 50-9	7	11
140	Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening. <i>EBioMedicine</i> , <b>2015</b> , 2, 782-3	8.8	
139	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. <i>Scientific Reports</i> , <b>2015</b> , 5, 17499	4.9	40
138	Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. <i>PLoS ONE</i> , <b>2015</b> , 10, e0127908	3.7	18

137	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , <b>2015</b> , 10, e0130142	3.7	339
136	The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. <i>PLoS ONE</i> , <b>2015</b> , 10, e0136731	3.7	7
135	Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 262-70	14.4	12
134	Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1341-1348	8.9	13
133	Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II- $\alpha$ amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel. <i>Clinical Breast Cancer</i> , <b>2015</b> , 15, 16-23	3	5
132	eComment. Does resected lymph-node number influence survival in non-small cell lung cancer?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2015</b> , 20, 227-8	1.8	
131	Neoadjuvant strategies for triple negative breast cancer: State-of-the-art and future perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2015</b> , 15, 15-25	2.2	5
130	Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 511-511	2.2	4
129	Sequential use of new agents (NAs) after docetaxel (DOC) first line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A pooled-analysis of the published studies.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 258-258	2.2	4
128	Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. <i>Oncotarget</i> , <b>2015</b> , 6, 12783-95	3.3	44
127	Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification. <i>American Journal of Cancer Research</i> , <b>2015</b> , 5, 2212-21	4.4	
126	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , <b>2015</b> , 4, 704-12	4.4	7
125	Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a New frontier?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2015</b> , 15, 307-13	2.2	10
124	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 4788-801	5.6	48
123	Platelets and their role in cancer evolution and immune system. <i>Translational Lung Cancer Research</i> , <b>2015</b> , 4, 713-20	4.4	11
122	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. <i>Translational Lung Cancer Research</i> , <b>2015</b> , 4, 721-7	4.4	22
121	Melanoma: oncogenic drivers and the immune system. <i>Annals of Translational Medicine</i> , <b>2015</b> , 3, 265	3.2	15
120	Molecular Typing of Lung Adenocarcinoma on Cytological Samples in the Next-Generation Sequencing Era <b>2015</b> , 367-379		

119	FOLFIRNOX for advanced pancreatic cancer (aPDAC) according to schedule and dose modifications: Clinical feasibility and impact of supportive care.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 372-372	2.2	
118	Prognostic stratification of node-negative NSCLC patients: is it worthwhile?. <i>Annals of Thoracic Surgery</i> , <b>2014</b> , 98, 1527	2.7	1
117	Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents. <i>Expert Review of Anticancer Therapy</i> , <b>2014</b> , 14, 1041-50	3.5	4
116	hMENa splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?. <i>Journal of Translational Medicine</i> , <b>2014</b> , 12, P12	8.5	78
115	BMI variation increases recurrence risk in women with early-stage breast cancer. <i>Future Oncology</i> , <b>2014</b> , 10, 2459-68	3.6	16
114	CXC and CC chemokines as angiogenic modulators in nonhaematological tumors. <i>BioMed Research International</i> , <b>2014</b> , 2014, 768758	3	43
113	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. <i>Expert Opinion on Drug Safety</i> , <b>2014</b> , 13, 535-49	4.1	22
112	Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma. <i>Pathology</i> , <b>2014</b> , 46, 523-6	1.6	2
111	ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 729-32	8.9	39
110	Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 847-56	14.4	15
109	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 90, 135-45	7	11
108	High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. <i>Gastric Cancer</i> , <b>2014</b> , 17, 442-9	7.6	45
107	Prognostic impact of alternative splicing-derived hMENa isoforms in resected, node-negative, non-small-cell lung cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 11054-63	3.3	23
106	Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a hard days night. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 3958-72	3.3	10
105	Prognostic value of ALK gene copy number (GCN) status for resected and metastatic non-small-cell lung cancer (NSCLC): A retrospective analysis of 205 patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e19059-e19059	2.2	
104	Suitability of clear cell renal cell carcinoma to heat shock proteins-inhibitors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 480-480	2.2	
103	Adenocarcinoma of the paraurethral glands: a case report. <i>Histology and Histopathology</i> , <b>2014</b> , 29, 1295-303	3.4	4
102	The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2013</b> , 139, 1563-8	4.9	3

101	Clinical meta-analyses of targeted therapies in adenocarcinoma. <i>Targeted Oncology</i> , <b>2013</b> , 8, 35-45	5	3
100	Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 471-6	3.3	19
99	Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?. <i>Lung Cancer</i> , <b>2013</b> , 80, 352-3	5.9	
98	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. <i>Expert Opinion on Drug Discovery</i> , <b>2013</b> , 8, 1381-97	6.2	6
97	PROFILING non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 597-608	4	6
96	A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. <i>Annals of Oncology</i> , <b>2013</b> , 24, 693-701	10.3	50
95	Chemotherapy in metastatic renal cell carcinoma today? A systematic review. <i>Anti-Cancer Drugs</i> , <b>2013</b> , 24, 535-54	2.4	58
94	Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors. <i>Lung Cancer Management</i> , <b>2013</b> , 2, 89-92	2.6	
93	Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, e105-6	8.9	13
92	Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. <i>Anti-Cancer Drugs</i> , <b>2013</b> , 24, 99-111	2.4	13
91	Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. <i>PLoS ONE</i> , <b>2013</b> , 8, e80478	3.7	88
90	Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2013</b> , 13, 872-86	2.2	5
89	First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 4511-9	5.6	12
88	Could a biomarkers-based patients selection help to plan a clinical trial with targeted agents (TA) for metastatic renal cell carcinoma (mRCC)? Interaction and power analysis of randomized trials (RCTs).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 399-399	2.2	
87	Activity of nab-paclitaxel (nab-P) monotherapy in heavily pretreated pancreatic cancer (aPDAC) patients (pts): A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e15057-e15057 <sup>2</sup>		
86	Targeted agents (TA) for advanced solid tumors (AST): What is the likelihood of being helped or harmed (LHH)? Assessing the clinical impact of therapies with FDA/EMA approval.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e17555-e17555	2.2	0
85	How much is reasonable to expect about overall survival (OS) benefit when designing studies with new drugs for patients affected by castration resistant prostate cancer (CRPC)? Meta-analysis of 23 randomized clinical trials (RCT) including 17,640 patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e16053-e16053	2.2	
84	HER2/neu gene determination in women screened for breast carcinoma: how screening programs reduce the skyrocketing cost of targeted therapy. <i>Anticancer Research</i> , <b>2013</b> , 33, 3705-10	2.3	2



83	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. <i>Cancer</i> , <b>2012</b> , 118, 1523-32	6.4	32
82	FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2012</b> , 31, 103	12.8	31
81	True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugs. <i>PLoS ONE</i> , <b>2012</b> , 7, e49689	3.7	10
80	Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. <i>Expert Review of Anticancer Therapy</i> , <b>2012</b> , 12, 1545-57	3.5	12
79	EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 672-80	8.9	26
78	Molecular and genetic bases of pancreatic cancer. <i>Current Drug Targets</i> , <b>2012</b> , 13, 731-43	3	21
77	Optimizing supportive measures for the safe administration of FOLFIRINOX as first-line treatment in advanced, inoperable pancreatic cancer (aPDAC) patients (pts) in routine clinical practice.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14661-e14661	2.2	1
76	PFS to predict long-term OS after first-line treatment for advanced renal cell carcinoma (aRCC): Correlation and power analysis of randomized trials (RCT).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4541-4541	2.2	1
75	Prognostic impact of FHIT, APC, and HER2 status in resected gastric cancer: A clinical-biological risk stratification model.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4076-4076	2.2	
74	Impact of single/dual HER2 inhibition and chemotherapy (CT) backbone upon pathologic complete response (pCR) in patients receiving neoadjuvant CT for operable/locally advanced breast cancer (O/LABC): A treatment-interaction analysis of randomized trials.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 630-630	2.2	
73	Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). <i>Lung Cancer</i> , <b>2011</b> , 73, 78-88	5.9	4
72	Maintenance therapy in NSCLC: why? To whom? Which agent?. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2011</b> , 30, 50	12.8	19
71	Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2011</b> , 30, 115	12.8	23
70	Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. <i>Supportive Care in Cancer</i> , <b>2011</b> , 19, 697-701	3.9	15
69	Acute emesis: moderately emetogenic chemotherapy. <i>Supportive Care in Cancer</i> , <b>2011</b> , 19 Suppl 1, S15-23	3.9	18
68	Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. <i>Supportive Care in Cancer</i> , <b>2011</b> , 19 Suppl 1, S25-32	3.9	30
67	Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential. <i>Supportive Care in Cancer</i> , <b>2011</b> , 19 Suppl 1, S33-6	3.9	10
66	Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2011</b> , 30, 10	12.8	68



65	Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2011</b> , 30, 54	12.8	28
64	Emerging pathways and future targets for the molecular therapy of pancreatic cancer. <i>Expert Opinion on Therapeutic Targets</i> , <b>2011</b> , 15, 1183-96	6.4	42
63	Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. <i>Annals of Oncology</i> , <b>2011</b> , 22, 2277-85	10.3	66
62	Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Annals of Oncology</i> , <b>2010</b> , 21 Suppl 5, v232-43	10.3	502
61	Early recurrence risk: aromatase inhibitors versus tamoxifen. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 1239-53	3.5	5
60	Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. <i>BMC Cancer</i> , <b>2010</b> , 10, 675	4.8	15
59	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2010</b> , 29, 58	12.8	41
58	Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy <b>2010</b> , 37-83		2
57	Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. <i>Oncology</i> , <b>2009</b> , 76, 254-61	3.6	37
56	Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. <i>Cancer</i> , <b>2009</b> , 115, 3446-56	6.4	60
55	Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. <i>Lung Cancer</i> , <b>2009</b> , 63, 50-7	5.9	37
54	A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. <i>Lung Cancer</i> , <b>2009</b> , 66, 365-71	5.9	71
53	Targeting targeted agents: open issues for clinical trial design. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2009</b> , 28, 66	12.8	15
52	Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity. <i>Anti-Cancer Drugs</i> , <b>2009</b> , 20, 109-14	2.4	2
51	Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer. <i>European Journal of Surgical Oncology</i> , <b>2008</b> , 34, 593-8	3.6	21
50	Thalidomide in small-cell lung cancer: is it a tombstone?. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 160; author reply 160	2.2	3
49	Progression-free survival as primary end point in advanced non-small-cell lung cancer: does the size matter?. <i>Annals of Oncology</i> , <b>2008</b> , 19, 402-3	10.3	5
48	Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. <i>Expert Opinion on Biological Therapy</i> , <b>2008</b> , 8, 1963-71	5.4	24

47	Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 109, 231-9	4.4	119
46	Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. <i>Supportive Care in Cancer</i> , <b>2008</b> , 16, 1375-80	3.9	10
45	Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. <i>Cancer</i> , <b>2008</b> , 112, 260-7	6.4	99
44	Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. <i>Cancer</i> , <b>2008</b> , 113, 238-46	6.4	51
43	The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer. <i>Reviews on Recent Clinical Trials</i> , <b>2008</b> , 3, 217-27	1.2	9
42	Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue?. <i>Clinical Breast Cancer</i> , <b>2007</b> , 7, 550-4	3	32
41	Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. <i>Cancer</i> , <b>2007</b> , 110, 525-33	6.4	83
40	Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparison. <i>European Urology</i> , <b>2007</b> , 51, 576-7	10.2	4
39	Aromatase inhibitors in post-menopausal metastatic breast carcinoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 1023-36	5.9	3
38	Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 176; author reply 176-7	9.7	2
37	Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice?. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 605-6; author reply 606-7	2.2	3
36	Adjuvant chemotherapy for non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S7-11	8.9	10
35	Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 227-32	2.4	12
34	Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 687-92	2.4	5
33	Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism. <i>Thrombosis Research</i> , <b>2007</b> , 119, 525-9	8.2	2
32	Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. <i>Cancer Investigation</i> , <b>2007</b> , 25, 102-5	2.1	31
31	Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. <i>Cancer</i> , <b>2006</b> , 106, 783-8	6.4	69
30	Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. <i>Cancer</i> , <b>2006</b> , 106, 2337-44	6.4	111

29	DNA repair by ERCC1 in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2590-1; author reply 2591	59.2	12
28	Chemotherapy-induced amenorrhea in early breast cancer. <i>Annals of Oncology</i> , <b>2006</b> , 17, 352	10.3	3
27	Does low-molecular-weight heparin influence cancer-related mortality?. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1604-6	10.3	6
26	Factorial design for randomized clinical trials. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1607-8	10.3	4
25	Non-small cell lung cancer: early stages. <i>Annals of Oncology</i> , <b>2006</b> , 17 Suppl 2, ii17-21	10.3	1
24	Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?. <i>Annals of Oncology</i> , <b>2006</b> , 17, 528-9	10.3	2
23	Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. <i>British Journal of Cancer</i> , <b>2006</b> , 94, 1789-96	8.7	27
22	Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients. <i>Cancer Treatment Reviews</i> , <b>2006</b> , 32, 325-32	14.4	15
21	Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. <i>Cancer Treatment Reviews</i> , <b>2006</b> , 32, 583-7	14.4	49
20	Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 608-16	7.5	18
19	Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?. <i>Chest</i> , <b>2006</b> , 130, 1808-16	5.3	30
18	Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study. <i>Anti-Cancer Drugs</i> , <b>2006</b> , 17, 345-51	2.4	3
17	Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors. <i>Anti-Cancer Drugs</i> , <b>2006</b> , 17, 1193-200	2.4	5
16	Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study. <i>Oncology</i> , <b>2005</b> , 68, 356-63	3.6	9
15	Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. <i>Cancer</i> , <b>2005</b> , 103, 672-9	6.4	39
14	Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. <i>Cancer</i> , <b>2005</b> , 104, 1237-45	6.4	30
13	New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. <i>Cancer</i> , <b>2005</b> , 104, 1335-42	6.4	32
12	Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2005</b> , 90, 319	4.4	2

11	Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening?. <i>Gut</i> , <b>2005</b> , 54, 891	19.2	1
10	Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7248-50; author reply 7250	2.2	11
9	Chemoradiotherapy for rectal cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 509-11; author reply 509-11	59.2	8
8	Treatment of resected non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1523-4; author reply 1523-4	59.2	5
7	Is cardiac troponin T serum level an accurate surrogate for acute doxorubicin-related myocardial injury?. <i>Annals of Oncology</i> , <b>2005</b> , 16, 1403-4	10.3	2
6	Zoledronic acid-associated thrombotic thrombocytopenic purpura. <i>Annals of Oncology</i> , <b>2004</b> , 15, 1847-8	10.3	5
5	Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. <i>Supportive Care in Cancer</i> , <b>2004</b> , 12, 446-53	3.9	29
4	Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. <i>Cancer</i> , <b>2004</b> , 101, 133-8	6.4	88
3	Contrast-enhanced computed tomographic colonography in the follow-up of colorectal cancer patients: a feasibility study. <i>European Radiology</i> , <b>2003</b> , 13, 883-9	8	41
2	A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 1870-5	8.7	18
1	Skin testing and hypersensitivity reactions to oxaliplatin. <i>Annals of Oncology</i> , <b>2003</b> , 14, 497-8	10.3	48